Evidence map›Paper›PMID 29117342›Full record

ArticleThe Journal of infectious diseases2017

The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.

Pren Naidoo, Grant Theron, Molebogeng X Rangaka, Violet N Chihota, Louise Vaughan, Zameer O Brey, Yogan Pillay

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04298905 (Leveraging mHealth to Enable and Adapt Community Health Worker Strategies to Improve TB/HIV Patient Outcomes in South Africa), which is not on this map. Cited by 163 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 6 pooled it
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04298905 naactive not recruitingnot on this mapstarted 2022, after this paper: background citation

Leveraging mHealth to Enable and Adapt Community Health Worker Strategies to Improve TB/HIV Patient Outcomes in South Africa (LEAP-TB-SA) Trial

TypeinterventionalSponsorJohns Hopkins UniversityRan2022 to 2026Enrolled62ConditionsAdherence, Patient, TB, HIV/AIDS, Care CoordinationArmsCHW mHealth patient intervention for trigger escalation
3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 6 syntheses or guidelines pooled it, 252 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Household Contact Tracing With Intensified Tuberculosis and Human Immunodeficiency Virus Screening in South Africa: A Cluster-Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018
    Trial
  13. Closing gaps through innovation in the tuberculosis pathology value chain.Journal of clinical tuberculosis and other mycobacterial diseases · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. A historical budget impact and expenditure analysis of meropenem and clavulanate-based treatment for adults with XDR-TB at a specialised TB hospital in South Africa.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2026
    Article
  19. Article
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Pren NaidooDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Grant TheronDST/NRF Centre of Excellence for Biomedical Tuberculosis Research.
Molebogeng X RangakaWellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Violet N ChihotaImplementation Research Division, Aurum Institute, Johannesburg, South Africa.
Louise VaughanDST/NRF Centre of Excellence for Biomedical Tuberculosis Research.
Zameer O BreyBill and Melinda Gates Foundation, Seattle, Washington.
Yogan PillayHIV/AIDS, TB, and Maternal and Child Health Branch, National Department of Health, Pretoria, South Africa.
Stellenbosch University · ZABill & Melinda Gates Foundation · USDepartment of Health · ZADesmond Tutu HIV Foundation · ZAUniversity College London · GBUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While tuberculosis incidence and mortality are declining in South Africa, meeting the goals of the End TB Strategy requires an invigorated programmatic response informed by accurate data. Enumerating the losses at each step in the care cascade enables appropriate targeting of interventions and resources. Methods: We estimated the tuberculosis burden; the number and proportion of individuals with tuberculosis who accessed tests, had tuberculosis diagnosed, initiated treatment, and successfully completed treatment for all tuberculosis cases, for those with drug-susceptible tuberculosis (including human immunodeficiency virus (HIV)-coinfected cases) and rifampicin-resistant tuberculosis. Estimates were derived from national electronic tuberculosis register data, laboratory data, and published studies. Results: The overall tuberculosis burden was estimated to be 532005 cases (range, 333760-764480 cases), with successful completion of treatment in 53% of cases. Losses occurred at multiple steps: 5% at test access, 13% at diagnosis, 12% at treatment initiation, and 17% at successful treatment completion. Overall losses were similar among all drug-susceptible cases and those with HIV coinfection (54% and 52%, respectively, successfully completed treatment). Losses were substantially higher among rifampicin- resistant cases, with only 22% successfully completing treatment. Conclusion: Although the vast majority of individuals with tuberculosis engaged the public health system, just over half were successfully treated. Urgent efforts are required to improve implementation of existing policies and protocols to close gaps in tuberculosis diagnosis, treatment initiation, and successful treatment completion.

Indexed as

Community Health ServicesAntibiotics, AntitubercularAntitubercular AgentsBlack PeopleCoinfectionCost of IllnessDisease EradicationDrug Resistance, Multiple, BacterialHIV InfectionsHumansIncidenceLost to Follow-UpMycobacterium tuberculosisPatient CareRifampinSouth AfricaAntibiotics, AntitubercularAntitubercular AgentsRifampincare cascadecase-findingcontinuum of careinitial loss to follow-uptreatment successTuberculosis

Identifiers

PMID29117342
PMCPMC5853316
OpenAlexW2767345805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.